Biological response modifiers: realizing their potential in cancer therapeutics
- 1 January 1986
- journal article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 7, 277-281
- https://doi.org/10.1016/0165-6147(86)90352-4
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Biological Response Modifiers: Their Potential and Limitations in Cancer TherapeuticsCancer Investigation, 1985
- Biological response modifiers: Preclinical evaluation and clinical activityCritical Reviews in Oncology/Hematology, 1984
- Treatment of Advanced Non-Hodgkin's Lymphoma with Recombinant Leukocyte a InterferonNew England Journal of Medicine, 1984
- Intrapleural administration of OK432 in cancer patients: Augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytesCancer Immunology, Immunotherapy, 1984
- Interferons in the treatment of human cancer.Journal of Clinical Oncology, 1984
- REGIONAL IMMUNOTHERAPY OF LUNG CANCER WITH INTRAPLEURAL B.C.G.The Lancet, 1976
- PROLONGING REMISSION IN MYELOBLASTIC LEUKÆMIA BY TICE-STRAIN BACILLUS CALMETTE-GUÉRINThe Lancet, 1974
- Immunotherapy for Acute Myelogenous LeukaemiaBritish Journal of Cancer, 1973
- ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIAThe Lancet, 1969